Hemophagocytic Lymphohistiocytoses

2
Pipeline Programs
1
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
GAMIFANTApproved
emapalumab-lzsg
Unknown Company
Interferon gamma Blocker [EPC]injection2018

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Swedish Orphan Biovitrum
2 programs
1
Emapalumab-LzsgPhase 2/31 trial
Blood Draws Data CollectionN/A1 trial
Active Trials
NCT06047210CompletedEst. Oct 2019
NCT03985423TerminatedEst. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Swedish Orphan BiovitrumEmapalumab-Lzsg
Swedish Orphan BiovitrumBlood Draws Data Collection

Clinical Trials (2)

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

Start: Jun 2020Est. completion: Jun 2021
Phase 2/3Terminated
NCT06047210Swedish Orphan BiovitrumBlood Draws Data Collection

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

Start: Dec 2016Est. completion: Oct 2019
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space